Teacher Retirement System of Texas Has $1.01 Million Stake in Veracyte, Inc. (NASDAQ:VCYT)

Teacher Retirement System of Texas decreased its position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 49.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,938 shares of the biotechnology company's stock after selling 33,036 shares during the quarter. Teacher Retirement System of Texas' holdings in Veracyte were worth $1,006,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of VCYT. US Bancorp DE lifted its holdings in shares of Veracyte by 57.4% during the 4th quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company's stock worth $70,000 after acquiring an additional 647 shares during the period. Jones Financial Companies Lllp lifted its stake in Veracyte by 49.7% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 237 shares during the last quarter. Proficio Capital Partners LLC bought a new position in shares of Veracyte in the 4th quarter valued at $1,179,000. Raymond James Financial Inc. acquired a new position in shares of Veracyte during the 4th quarter worth $1,626,000. Finally, PNC Financial Services Group Inc. lifted its position in shares of Veracyte by 9.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 25,439 shares of the biotechnology company's stock worth $1,007,000 after buying an additional 2,115 shares during the last quarter.

Wall Street Analysts Forecast Growth

VCYT has been the subject of several research analyst reports. UBS Group lowered their target price on Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Guggenheim cut their target price on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Stephens reiterated an "overweight" rating and set a $45.00 price target on shares of Veracyte in a report on Wednesday, March 26th. Wall Street Zen downgraded Veracyte from a "buy" rating to a "hold" rating in a report on Saturday, June 28th. Finally, Needham & Company LLC dropped their target price on Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $40.90.

Veracyte Stock Down 1.6%

NASDAQ:VCYT traded down $0.43 during trading hours on Monday, reaching $26.65. The company had a trading volume of 663,848 shares, compared to its average volume of 979,726. Veracyte, Inc. has a twelve month low of $19.73 and a twelve month high of $47.32. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of 65.00 and a beta of 2.07. The business's 50-day simple moving average is $27.72 and its two-hundred day simple moving average is $33.28.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.